natgillin/translations-raw huggingface dataset:
The active substance in Aldurazyme, laronidase, is a copy of the human enzyme α L iduronidase. 
Aldurazyme toimeaine laronidaas on inimorganismis leiduva loodusliku ensüümi α-L-iduronidaasi koopia.
Why has Aldurazyme been approved? 
Miks Aldurazyme heaks kiideti?
In patients under five years of age, the most common side effects (seen in more than 1 patient in 10) are increased blood pressure, decreased oxygen saturation (a measure of how well the lungs are working), tachycardia (rapid heart rate), pyrexia and chills. 
Alla 5-aastastel patsientidel on kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) kõrgenenud vererõhk, vere hapnikuküllastuse (kopsutalitluse näitaja) vähenemine, tahhükardia (südame löögisageduse suurenemine), püreksia (palavik) ja külmavärinad.
The full EPAR for Aldurazyme can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst Aldurazyme kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Kui vajate Aldurazymega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Aldurazyme is a solution for infusion (drip) into a vein that contains the active substance laronidase. 
Aldurazyme on infusioonilahus (veeni tilgutatav lahus), mis sisaldab toimeainena laronidaasi.
How has Aldurazyme been studied? 
Kuidas Aldurazymet uuriti?
Laronidase is used as ‘enzyme replacement therapy', which means that it replaces the enzyme that is missing in patients with MPS I. This controls the symptoms of MPS I, improving the patient's quality of life. 
Laronidaasi kasutatakse ensüümiasendusraviks, st see asendab I tüüpi mukopolüsahharidoosiga patsiendi organismis puuduvat ensüümi.
How is Aldurazyme used? 
Kuidas Aldurazymet kasutatakse?
What benefit has Aldurazyme shown during the studies? 
Milles seisneb uuringute põhjal Aldurazyme kasulikkus?
What is Aldurazyme used for? 
Milleks Aldurazymet kasutatakse?
Aldurazyme has been compared with placebo (a dummy treatment) in 45 patients aged six years and over with a confirmed diagnosis of MPS I. The main measure of effectiveness was the forced vital capacity (FVC, a measure of how well the lungs are working) and the distance the patients could walk over six minutes. 
Efektiivsuse põhinäitajad olid forsseeritud vitaalkapatsiteet (FVC - suurim õhumaht, mille patsient suudab pärast suurimat sissehingamist jõuliselt välja hingata) ja teepikkus, mille patsiendid suutsid läbida kuue minuti jooksul.
How does Aldurazyme work? 
Kuidas Aldurazyme toimib?
The medicine can only be obtained with a prescription. 
Aldurazyme on retseptiravim.
MA (EU) number (Invented) name 
ML (EL) number
Immediate Packaging 
Manustamisviis Pakend
Pack size 
Paki suurus
Content (concentration) 
Pakendi sisu (kontsentrat sioon)
This summary was last updated in 12-2013. 
Kokkuvõtte viimane uuendus: 12-2013.
The following infusions are 250 mg/m2 given over one hour. 
Järgnevad infusiooniannused on 250 mg/m2 ühe tunni jooksul.
Erbitux is given once a week. 
Erbituxi manustatakse üks kord nädalas.
The full EPAR for Erbitux can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Euroopa avaliku hindamisaruande täistekst Erbituxi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Erbitux on 29 June 2004. 
Euroopa Komisjon andis Erbituxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 29. juunil
Skin reactions are seen in more than 80% of patients. 
Nahareaktsioone on esinenud enam kui 80%-l patsientidest.
Patients must also be closely observed for any signs of allergic reaction for at least one hour after the end of the infusion. 
Patsiente tuleb ka hoolikalt jälgida allergilise reaktsiooni sümptomite suhtes vähemalt 1 tund pärast infusiooni.
Other information about Erbitux 
Muu teave Erbituxi kohta
The CHMP decided that Erbitux's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Inimravimite komitee otsustas, et Erbituxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
The first infusion is given at a dose of 400 mg per square metre body surface area (calculated using the patient's height and weight) over two hours. 
Esmane infusiooniannus on 400 mg kehapindala ruutmeetri kohta (arvutatud patsiendi pikkuse ja kehamassi järgi) kahe tunni jooksul.
• together with the oxaliplatin-containing treatment FOLFOX in patients who have not been treated before; 
• koos oksaliplatiini sisaldava FOLFOX-raviga patsientidel, keda varem ei ole ravitud;
Erbitux can be associated with severe reactions during the infusion, so the patients must be monitored carefully while the medicine is being given. 
Erbituxi infusiooni ajal võib tekkida tugevaid reaktsioone ning patsiente peab ravimi manustamise ajal hoolikalt jälgima.
• together with anticancer treatments containing irinotecan; 
• koos irinotekaani sisaldava vähiraviga;
This is a summary of the European public assessment report (EPAR) for Erbitux. 
See on ravimi Erbitux Euroopa avaliku hindamisaruande kokkuvõte.
The most common side effects with Erbitux (seen in more than 1 patient in 10) are skin reactions such as rash, hypomagnesaemia (low blood magnesium levels), mild or moderate reactions linked to the infusion (such as fever, chills, dizziness and difficulty breathing), mucositis (inflammation of the lining of the mouth) and raised levels of some liver enzymes. 
Erbituxi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on nahareaktsioonid, nagu lööve, hüpomagneseemia (vere väike magneesiumisisaldus), kerged või mõõdukad infusioonireaktsioonid (palavik, külmavärinad, peapööritus ja hingamisraskused), mukosiit (suu limaskesta põletik) ja maksaensüümide suurenenud sisaldus.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Erbitux. 
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit Erbitux ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
Between 79 and 89% of colorectal cancers and more than 90% of squamous cell cancers of the head and neck have EGFR on their cell surfaces. 
Epidermaalse kasvuteguri retseptoreid leidub 79-89% kolorektaalsete vähivormide ja enam kui 90% pea- ja kaelapiirkonna lamerakuliste vähivormide rakkude pinnal.
• on its own when previous treatment containing oxaliplatin and irinotecan has failed and the patient cannot receive irinotecan. 
• ainsa ravimina, kui varasem ravi oksaliplatiini ja irinotekaaniga on ebaõnnestunud ning patsient ei saa kasutada irinotekaani.
For more information about treatment with Erbitux, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Erbituxiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
When RAS genes (such as KRAS) are mutated they can stimulate the tumour cells to grow without being switched on by EGFR, so Erbitux would not be expected to be of much help. 
Muteerunud RAS-geenid (näiteks KRAS) võivad stimuleerida kasvajarakkude kasvu ka ilma EGFR-poolse aktiveerimiseta, mistõttu Erbituxist ei oleks suurt abi.
Before receiving Erbitux, the patient must be given an antihistamine and a corticosteroid to prevent an allergic reaction. 
Enne Erbituxi esmakordset manustamist tuleb patsientidele anda antihistamiini ja kortikosteroide allergilise reaktsiooni ennetamiseks.
When it is used with radiotherapy, Erbitux is started one week before the radiotherapy starts and continued until the radiotherapy has finished. 
Kui Erbituxi kasutatakse koos kiiritusraviga, alustatakse ravi Erbituxiga üks nädal enne kiiritusravi algust ja jätkatakse kuni kiiritusravi lõpetamiseni.
EPAR summary for the public cetuximab 
Kokkuvõte üldsusele tsetuksimaab
For the full list of all side effects reported with Erbitux, see the package leaflet. 
Erbituxi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
Erbitux should only be given under the supervision of a doctor who has experience in the use of anticancer medicines in a setting where facilities for resuscitation are available. 
Ravi Erbituxiga tohib alustada üksnes vähiravimite kasutamises kogenud arsti järelevalve all ja haiglakeskkonnas, kus on olemas elustamisvahendid.
• the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination. 
• teises uuringus osales 442 korduva või metastaatilise vähiga patsienti ning selles uuriti Erbituxi toimet selle lisamisel plaatinat sisaldava vähiravimi kombinatsioonile.
When it is used on its own or with other anticancer medicines, Erbitux is continued for as long as the patient responds. 
Kui Erbituxi kasutatakse ainsa ravimina või koos teiste vähiravimitega, kestab ravi nii kaua, kui patsiendil tekib ravivastus.
What is Erbitux? 
Mis on Erbitux?
In cancer that is recurrent (when it has come back after previous treatment) or metastatic, Erbitux is used with a ‘platinum-based' anticancer medicine combination (including medicines such as cisplatin or carboplatin). 
Korduva (haigus on pärast ravi taastunud) või metastaatilise vähi korral kasutatakse Erbituxi koos plaatinat sisaldava vähiravimiga (näiteks tsisplatiin ja karboplatiin).
Why has Erbitux been approved? 
Miks Erbitux heaks kiideti?
Erbitux must not be used with oxaliplatin-containing chemotherapy for metastatic colorectal cancer in patients with mutated RAS or for whom RAS status is unknown. 
Erbituxi ei tohi kasutada koos oksaliplatiini sisaldava keemiaraviga, kui patsiendil on metastaatiline muteerunud RAS-geeniga kolorektaalvähk või kui patsiendi RAS-geeni staatus ei ole teada.
What is the risk associated with Erbitux? 
Mis riskid Erbituxiga kaasnevad?
• the first study in patients who had taken chemotherapy before did not look at RAS mutations, but in the other two studies, patients with wild-type KRAS in their tumours lived for longer without their disease getting worse when Erbitux was added to their treatment. 
• Esimeses uuringus varem keemiaravi saanud patsientidel ei vaadeldud RAS-geeni muteerumist, kuid ülejäänud kahes uuringus kulus muteerumata KRAS-geeniga patsientidel rohkem aega haiguse süvenemiseni kui ravile lisati Erbituxi.
• three studies involved 2,199 patients whose disease had got worse while they were on previous treatment including irinotecan, oxaliplatin or both, or who could not receive these medicines. 
• kolmes uuringu osales 2199 patsienti, kes ei saanud kasutada irinotekaani ja oksaliplatiini või kelle haigus süvenes neid ravimeid kas eraldi või koos kasutades.
These types of cancer affect the cells of the lining of the mouth or the throat, or of organs such as the larynx (voice box). 
Need vähivormid mõjutavad suu või kõri limaskesta rakke või hääleaparaati.
Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain ‘wild-type' (non-mutated) versions of a family of genes called ‘RAS'. 
Erbituxi kasutatakse patsientidel, kelle vähirakkude pinnal on valku, mida nimetatakse epidermaalse kasvuteguri retseptoriks (EGFR), ja kelle vähirakud sisaldavad muteerumata RAS-geeni.
Erbitux is a solution for infusion (drip into a vein) that contains the active substance cetuximab. 
Erbitux on infusioonilahus (veeni tilgutatav lahus), mis sisaldab toimeainena tsetuksimaabi.
For metastatic cancer of the colon or rectum, Erbitux was studied in six main studies: 
Metastaatilise käär- ja pärasoolevähi korral uuriti Erbituxi kuues põhiuuringus:
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) in the body. 
Erbituxi toimeaine tsetuksimaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva teatud aine (antigeeni) ja seondub sellega.
Patients who had failed both oxaliplatin and irinotecan treatment lived for an average of 3.6 months without their disease getting worse with Erbitux, compared with 1.9 months in those receiving best supportive care alone (the treatment of symptoms but not the cancer itself). 
Patsientidel, kelle ravi irinotekaani ja oksaliplatiiniga ei andnud tulemusi, kulus haiguse süvenemiseni Erbituxi lisamisel keskmiselt 3,6 kuud ning üksnes parimat toetavat ravi (sümptomite, kuid mitte vähi ravi) saanud patsientidel 1,9 kuud.
• two studies involved 1,535 patients who had not received chemotherapy before, looking at the effects of adding Erbitux to a treatment combination containing either irinotecan or oxaliplatin (FOLFOX); a third study looked also at the effects of adding Erbitux to two treatment combinations containing oxaliplatin (one of which was similar to FOLFOX) in 1,630 patients. 
Uuringus vaadeldi Erbituxi lisamise toimet irinotekaani või oksaliplatiini (FOLFOX) ravile; kolmandas uuringus (1630 patsienti) vaadeldi samuti Erbituxi lisamise toimet kahele oksaliplatiini sisaldava ravi kombinatsioonile (neist üks oli sarnane FOLFOXiga);
All of the studies looked at how long the patients lived without their cancer getting worse or how long they survived. 
Kõikides uuringutes vaadeldi aega vähi progresseerumiseni ja patsientide elulemust.
• in patients who had not received chemotherapy before, patients who had wild-type KRAS in their tumours lived for longer without their disease getting worse when they received Erbitux in addition to chemotherapy including irinotecan (9.9 months compared with 8.4 months, on average). 
• Muteerumata KRAS-geeniga kasvajatega patsientidel, kes ei olnud varem keemiaravi saanud, kulus haiguse süvenemiseni rohkem aega, kui nad said lisaks irinotekaani sisaldavale keemiaravile ka Erbituxi (haiguse süvenemiseni Erbituxi lisamisel kulus keskmiselt 9,9 kuud võrreldes 8,4 kuuga, kui seda ei lisatud).
In recurrent or metastatic head and neck cancer, survival was longer when Erbitux was added to a platinum-based anticancer medicine combination (10.1 months compared with 7.4 months, on average). 
Pea- ja kaelapiirkonna korduva vähi korral oli Erbituxi lisamisel plaatinat sisaldava vähiravimi kombinatsioonile elulemus pikem (10,1 kuud võrreldes 7,4 kuuga).
However, in the third study, patients with wild-type KRAS only survived overall for 16.3 months when Erbitux was added to the another oxaliplatin-based treatment similar to FOLFOX, compared with 18.2 months when the oxaliplatin-based treatment was used alone. 
Kolmandas uuringus oli Erbituxi lisamisel oksaliplatiini sisaldavale keemiaravile (sarnane FOLFOX-raviga) muteerumata KRAS-geeniga patsientide elulemus 16,3 kuud võrreldes 18,2 kuuga, kui kasutati ainult oksaliplatiini sisaldavat ravi.
In patients receiving Erbitux in combination with oxaliplatin-containing chemotherapy (FOLFOX) patients with wild-type RAS lived for longer without their disease getting worse compared with patients on FOLFOX alone (12.0 months compared with 5.8 months, on average). 
Kui oksaliplatiini sisaldavale keemiaravile (FOLFOX) lisati Erbituxi, kulus muteerumata RAS-geeniga patsientidel haiguse süvenemiseni rohkem aega kui ainult FOLFOX-ravi korral (keskmiselt 12,0 kuud võrreldes 5,8 kuuga).
For cancers of the head and neck, Erbitux was investigated in two main studies: 
Erbituxi tõhusust pea- ja kaelapiikonna kasvajate ravis uuriti kahes põhiuuringus:
One of the studies also looked at the results separately in patients whose tumours carried wild-type forms of all RAS genes and patients with mutated forms of any RAS gene. 
Ühes uuringus vaadeldi eraldi ka muteerumata ja muteerunud RAS-geenidega kasvajatega patsientide tulemusi.
What benefit has Erbitux shown during the studies? 
Milles seisneb uuringute põhjal Erbituxi kasulikkus?
How is Erbitux used? 
Kuidas Erbituxi kasutatakse?
What is Erbitux used for? 
Milleks Erbituxi kasutatakse?
How has Erbitux been studied? 
Kuidas Erbituxi uuriti?
How does Erbitux work? 
Kuidas Erbitux toimib?
Erbitux is also used to treat ‘squamous cell' cancers of the head and neck. 
Erbituxi kasutatakse ka pea ja kaela lamerakk-kartsinoomide raviks.
Most of the studies looked at the results separately in patients whose tumours had wildtype KRAS (one of the types of RAS genes) and patients whose tumours had mutated KRAS. 
Enamikus uuringutes vaadeldi eraldi muteerumata ja muteerunud KRAS-geeniga (RAS-geeni alaliik) kasvajatega patsientide tulemusi.
In locally advanced cancer (when the tumour has grown but has not spread), Erbitux is given in combination with radiotherapy (treatment with radiation). 
Lokaalselt kaugelearenenud (metastaasideta) vähi korral kasutatakse Erbituxi koos kiiritusraviga.
In locally advanced head and neck cancers, the patients lived for longer without their disease getting worse when Erbitux was added to radiotherapy (24.4 months compared with 14.9 months, on average). 
Pea- ja kaelapiirkonna paikse vähi korral kulus haiguse süvenemiseni Erbituxi lisamisel kiiritusravile rohkem aega (keskmiselt 24,4 kuud võrreldes 14,9 kuuga).
• the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy; 
• esimeses uuringus osales 424 lokaalselt kaugelearenenud vähiga patsienti.
In the studies of cancer of the colon or rectum, Erbitux was shown overall to increase the time patients lived without their cancer getting worse or how long they survived: 
Käär- ja pärasoolevähi uuringutes osalenud patsientidel, kes said Erbituxi, kulus haiguse süvenemiseni rohkem aega või elasid nad üldiselt kauem järgmistel juhtudel.
Patients who had failed oxaliplatin treatment lived for an average of 4.0 months without their disease getting worse with Erbitux plus irinotecan, compared with 2.6 months in those receiving irinotecan alone. 
Progresseerumiseta elulemus oli patsientidel, kelle ravi oksaliplatiiniga ei andnud tulemusi, Erbituxi ja irinotekaani kasutamisel 4 kuud ning ainult irinotekaani kasutamisel 2,6 kuud.
Erbitux is used to treat metastatic cancer of the colon or rectum (large intestine). 
Erbituxi kasutatakse metastaatilise käär- või pärasoolevähi raviks.
The medicine can only be obtained with a prescription. 
Erbitux on retseptiravim.
EGFR is involved in switching on genes called RAS that are involved in the growth of cells; by attaching to EGFR, cetuximab prevents this from happening in the tumour cells and helps stop them growing. 
EGFR-ga seondudes takistab tsetuksimaab seda protsessi vähirakkudes, pärssides nende kasvu.
Erbitux is given in the following ways: 
Seda tohib kasutada nii:
United Kingdom Teva Uk Limited 
Teva Uk Limited
United Kingdom Norton Healthcare Ltd T/A Ivax 
Norton Healthcare Ltd T/A Ivax
Genéricos Españoles Laboratorio, S.A. 
G,E,S, Genéricos Españoles Laboratorio, S.A.
Gastro-Resistant Capsule 
Gastroresistentne kapsel
United Kingdom Noridem Enterprises Ltd Sodium Valproate Noridem Enterprises 
Noridem Enterprises Ltd Naatriumvalproaat Noridem Enterprises
Valproate Magnesium 10000mg/100 Ml 
Magneesiumvalproaat 10000 mg/100 ml
United Kingdom Winthrop Pharmaceuticals Uk Ltd 
Winthrop Pharmaceuticals Uk Ltd
Prolonged-Release Capsule 
Toimeainet prolongeeritult vabastav kapsel
Sanofi-Aventis Cyprus Ltd 
Sanofi-Aventis Kypros Ltd
Sodium Valproate Wockhardt Uk 
Naatriumvalproaat Wockhardt Uk
ácido Valpróico Generis Valproic Acid 400mg/4 Ml 
ácido Valpróico Generis Valproehape 400 mg/4 ml
Sodium Valproate Bp 200mg 
Naatriumvalproaat Bp 200 mg
United Kingdom Aventis Pharma Ltd Epilim Chrono 
Aventis Pharma Ltd Epilim Chrono
Depakine Chrono 500 Valproic Acid 145.14mg Tablet, Sodium 
Depakine Chrono 500 Valproehape 145,14 mg tablett,
Solution For Injection Intravenous Use 
Süste/infusioonilahus Intravenoosne
Valproate Semisodium 269.1mg Tablet 
Seminaatriumvalproaat 269,1 mg tablett
Valproate Semisodium 538.2mg Tablet 
Seminaatriumvalproaat 538,2 mg tablett
Natriumvalproat Aristo Sodium Valproate 300mg G 
Natriumvalproat Aristo Naatriumvalproaat 300 mg G
Sodium Valproate Wockhardt 
Naatriumvalproaat Wockhardt
Valproic Acid 43.38mg/Ml 
Valproehape 43,38 mg/ml
Intravenous Use 
Intravenoosne
ácido Valproico G.E.S Sodium Valproate 400mg Vial 
ácido Valproico G.E.S Naatriumvalproaat 400 mg viaal
United Kingdom Aventis Pharma Ltd Depakote 
Aventis Pharma Ltd Depakote
Valproic Acid 145mg G, Sodium Valproate 333mg G 
Valproehape 145 mg G, Naatriumvalproaat 333 mg G
Valproic Acid 87mg G, Sodium Valproate 200mg Tablet 
Valproehape 87 mg G, Naatriumvalproaat 200 mg tablett
Valproat Ratiopharm Valproic Acid 145mg G, Sodium Valproate 
Valproat Ratiopharm Valproehape 145 mg G, Naatriumvalproaat
United Kingdom Aventis Pharma Ltd Epilim 
Aventis Pharma Ltd Epilim
Natriumvalproaat Teva Valproic Acid 145mg G, Sodium Valproate 
Natriumvalproaat Teva Valproehape 145 mg G, Naatriumvalproaat
Modified-Release Tablet Oral Use 
Toimeainet modifitseeritult vabastav tablett
Depakine Chrono 300 Valproic Acid 87mg Tablet, Sodium 
Depakine Chrono 300 Valproehape 87 mg tablett,
Prolonged-Release Granules 
Toimeainet prolongeeritult vabastavad graanulid
Valproic Acid 50mg/Ml 
Valproehape 50 mg/ml
Sodium Valproate 400mg Vial 
Naatriumvalproaat 400 mg viaal
Sodium Valproate Winthrop 
Naatriumvalproaat Winthrop
Sodium Valproate 1000mg Container 
Naatriumvalproaat 1000 mg konteiner
Sodium Valproate Ivax Sodium Valproate 200mg/5 Ml 
Naatriumvalproaat Ivax Naatriumvalproaat 200 mg/5 ml
Solution For Injection/Infusion 
Süste/infusioonilahuse kontsentraat
ácido Valpróico Generis Valproic Acid 145mg Tablet, Sodium 
ácido Valpróico Generis Valproehape 145 mg tablett,
ácido Valpróico Generis Valproic Acid 87mg Tablet, Sodium 
ácido Valpróico Generis Valproehape 87 mg tablett,
Powder And Solvent For Solution For Injection/Infusion 
Süste/infusioonilahuse pulber ja lahusti
Prolonged-Release Granules In Sachet 
Toimeainet prolongeeritult vabastavad graanulid kotikeses
Sodium Valproate 500mg 
Naatriumvalproaat 500 mg
Sodium Valproate 200mg 
Naatriumvalproaat 200 mg
Sodium Valproate 500mg Container 
Naatriumvalproaat 500 mg konteiner
Valproate Retard Mylan Sodium Valproate 500mg Tablet 
Valproate Retard Mylan Naatriumvalproaat 500 mg tablett
Austria sanofi-aventis GmbH Depakine Chronosphere Valproic Acid 145.14mg Sachet, Sodium 
Austria sanofi-aventis GmbH Depakine Chronosphere Valproehape 145,14 mg kotike,
Espa-Valept Retard Sodium Valproate 300mg Tablet 
Espa-Valept Retard Naatriumvalproaat 300 mg tablett
Valproate Retard Mylan Sodium Valproate 300mg Tablet 
Valproate Retard Mylan Naatriumvalproaat 300 mg tablett
Depakine Chronosphere Valproic Acid 217.75mg Sachet, Sodium 
Depakine Chronosphere Valproehape 217,75 mg kotike,
Sodium Valproate 400mg Container 
Naatriumvalproaat 400 mg konteiner
Sanofi-Aventis Aebe Depakine Chronosphere Valproic Acid 29.03mg Sachet, Sodium 
Sanofi-Aventis Aebe Depakine Chronosphere Valproehape 29,03 mg kotike,
Austria sanofi-aventis GmbH Depakine Chronosphere Valproic Acid 72.61mg Sachet, Sodium 
Austria sanofi-aventis GmbH Depakine Chronosphere Valproehape 72,61 mg kotike,
Sanofi-Aventis Aebe Depakine Chronosphere Valproic Acid 290.27mg Sachet, Sodium 
Sanofi-Aventis Aebe Depakine Chronosphere Valproehape 290,27 mg kotike,
Sanofi-Aventis Aebe Depakine Chronosphere Valproic Acid 72.61mg Sachet, Sodium 
Sanofi-Aventis Aebe Depakine Chronosphere Valproehape 72,61 mg kotike,
Valproat Neuraxpharm Sodium Valproate 60mg/Ml 
Valproat Neuraxpharm Naatriumvalproaat 60 mg/ml
Valproate Magnesium 500mg Tablet 
Magneesiumvalproaat 500 mg tablett
Sodium Valproate 300mg Capsule 
Naatriumvalproaat 300 mg kapsel
Sodium Valproate 150mg Capsule 
Naatriumvalproaat 150 mg kapsel
Valproate Semisodium 250mg Tablet 
Seminaatriumvalproaat 250 mg tablett
Valproate 333mg Tablet 
333,3 mg tablett
United Kingdom Aventis Pharma Ltd Epilim Chronosphere Valproic Acid 72.61mg Sachet, Sodium 
Aventis Pharma Ltd Epilim Chronosphere Valproehape 72,61 mg kotike,